{"entity":{"id":"breast-cancer-trials","kind":"company","name":"Breast Cancer Trials","aka":["BCT","Australia and New Zealand Breast Cancer Trials Group","ANZBCTG"],"tldr":"The Australian and New Zealand breast cancer trials group, a Breast International Group partner in SOFT/TEXT, APHINITY, OlympiA and POSITIVE.","summary":"Founded in 1978 as the ANZ Breast Cancer Trials Group and renamed Breast Cancer Trials, it is one of the longest-running academic breast cancer groups and a founding member of the Breast International Group. It co-led the IBCSG SOFT and TEXT trials of ovarian suppression, contributed to APHINITY, OlympiA and the POSITIVE pregnancy-interruption study, and runs its own trials such as EXPERT (omitting radiotherapy in low-genomic-risk luminal A disease) and DECRESCENDO. A large consumer advisory panel shapes protocol design. Trials are coordinated from Newcastle with sites across Australia and New Zealand.","asOf":"2026-09-09","links":[{"label":"Breast Cancer Trials","url":"https://www.breastcancertrials.org.au"},{"label":"Clinical trials","url":"https://www.breastcancertrials.org.au/clinical-trials/"}],"tags":["cooperative-group"],"related":["olaparib","trastuzumab"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":["hormonal"],"technologies":["endocrine-therapy","parp-inhibitor"],"targets":[],"drugs":[],"companies":["big","etop-ibcsg"],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["soft-text","olympia","aphinity"],"people":["loi-sherene","sunil-lakhani"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["SOFT / TEXT (with IBCSG)","OlympiA and APHINITY (with BIG)","EXPERT (radiotherapy omission)","POSITIVE (pregnancy after endocrine therapy)"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Newcastle, NSW","country":"AU","companyType":"cooperative-group","website":"https://www.breastcancertrials.org.au","founded":1978,"investors":[],"funding":[]},"route":"/companies/breast-cancer-trials/","neighbours":{"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"company":[{"id":"big","kind":"company","name":"Breast International Group (BIG)","route":"/companies/big/"},{"id":"etop-ibcsg","kind":"company","name":"ETOP IBCSG Partners Foundation","route":"/companies/etop-ibcsg/"}],"institution":[{"id":"cancer-council-australia","kind":"institution","name":"Cancer Council Australia","route":"/institutions/cancer-council-australia/"},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"trial":[{"id":"aphinity","kind":"trial","name":"APHINITY","route":"/trials/aphinity/"},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/"},{"id":"soft-text","kind":"trial","name":"SOFT & TEXT","route":"/trials/soft-text/"}],"person":[{"id":"prudence-francis","kind":"person","name":"Prudence A. Francis","route":"/people/prudence-francis/"},{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/"},{"id":"sunil-lakhani","kind":"person","name":"Sunil Lakhani","route":"/people/sunil-lakhani/"}]}}